1st Biden-Trump Debate of 2024: What They Got Wrong, and Right
A debate marked by President Joe Biden鈥檚 faltering performance featured clashes over insulin costs, inflation, abortion, immigration, and Jan. 6.
Drugs
141 - 160 of 1,305 Results
-
SCOTUS Rejects Abortion Pill Challenge 鈥 For Now聽
Episode 351The Supreme Court has dismissed a challenge to the FDA鈥檚 approval of the abortion pill mifepristone, ruling unanimously that the anti-abortion doctor group that filed the suit lacked standing. But abortion opponents are expected to pursue other strategies to ban or restrict the medication. Meanwhile, the Biden administration moves to stop the inclusion of medical debt on individual credit reports, and former President Donald Trump tries to claim credit for $35 insulin. Anna Edney of Bloomberg News, Rachana Pradhan of 吃瓜不打烊, and Emmarie Huetteman of 吃瓜不打烊 join 吃瓜不打烊 chief Washington correspondent Julie Rovner to discuss these stories and more. Also this week, Rovner interviews KFF president and CEO Drew Altman about KFF鈥檚 new 鈥淗ealth Policy 101鈥 primer.
-
Biden Plan To Save Medicare Patients Money on Drugs Risks Empty Shelves, Pharmacists Say
President Joe Biden is campaigning for reelection on his efforts to cut costs for Medicare patients at the pharmacy counter. But independent pharmacists say one strategy makes it unaffordable for them to keep some brand-name medicines in stock.
By Susan Jaffe -
-
Readers Issue Rx for Clogged ERs and Outrageous Out-of-Pocket Costs
吃瓜不打烊 gives readers a chance to comment on a recent batch of stories.
-
Journalists Talk Cost of Weight Loss Drugs and Lack of Obesity Doctors to Manage Their Use
吃瓜不打烊 and California Healthline staff made the rounds on national and local media this week to discuss topical stories. Here鈥檚 a collection of their appearances.
Waiting for SCOTUS
Episode 349June is when the Supreme Court typically issues rulings in the major cases it hears during that year鈥檚 term. This year, those interested in health policy are awaiting decisions in two abortion-related cases and one that could reshuffle the way health policies (and all other federal policies) are made. In this special episode, KFF鈥檚 Laurie Sobel, associate director for women鈥檚 health policy, joins Julie Rovner for a review of the cases and a preview of how the court might rule.
-
An Obscure Drug Discount Program Stifles Use of Federal Lifeline by Rural Hospitals
A disconnect between two federal programs meant to help keep hospitals afloat discourages struggling rural facilities from accepting the aid.
-
Journalists Zero In on Bird Flu and Weight Loss Drugs
吃瓜不打烊 and California Healthline staff made the rounds on national and local media this week to discuss their stories. Here鈥檚 a collection of their appearances.
-
High Price of Popular Diabetes Drugs Deprives Low-Income People of Effective Treatment
The makers of Ozempic and Mounjaro charge list prices of around $1,000 a month for the diabetes and obesity drugs, and insurers are reluctant to pick up the tab. Often, low-income patients have to resort to less effective treatments.
-
Journalists Broach Topics From Treating Shooting Victims to Sunscreen Safety
吃瓜不打烊 and California Healthline staffers made the rounds on national and local media in the last couple of weeks to discuss topical stories. Here鈥檚 a collection of their appearances.
-
Clean Needles Save Lives. In Some States, They Might Not Be Legal.
As billions of dollars from settlements with opioid manufacturers and distributors go to state and local governments, efforts to reduce the epidemic鈥檚 harm can be hamstrung by drug paraphernalia laws. Health authorities say distributing clean syringes to users can save lives, but in states like Pennsylvania, it may be illegal.
-
What鈥檚 Keeping the US From Allowing Better Sunscreens?
A decade after Congress told the FDA to expedite the approval of more effective sunscreens, the federal government still has not approved sunscreen ingredients that are safely being used around the world. Meanwhile, skin cancer is the nation鈥檚 most common cancer.
-
Amgen Plows Ahead With Costly, Highly Toxic Cancer Dosing Despite FDA Challenge
The FDA told Amgen to test whether a quarter-dose of its lung cancer drug worked as well as the amount recommended on the product label. It did and with fewer side effects. But Amgen is sticking to the higher dose 鈥 which earns it an additional $180,000 a year per patient.
By Arthur Allen Abortion Access Changing Again in Florida and Arizona
Episode 345A six-week abortion ban took effect in Florida this week, dramatically restricting access to the procedure not just in the nation鈥檚 third-most-populous state but across the South. Patients from states with even more restrictive bans had been flooding in since the overturn of Roe v. Wade in 2022. Meanwhile, the CEO of the health behemoth UnitedHealth Group appeared before committees in both the House and Senate, where lawmakers grilled him about the February cyberattack on subsidiary Change Healthcare and how its ramifications are being felt months later. Alice Miranda Ollstein of Politico, Sarah Karlin-Smith of the Pink Sheet, and Rachana Pradhan of 吃瓜不打烊 join 吃瓜不打烊鈥 Julie Rovner to discuss these stories and more. Plus, for 鈥渆xtra credit,鈥 the panelists suggest health policy stories they read this week they think you should read, too.
-
Journalists Drill Down on Bird Flu Risks, Opioid Settlement Payouts, and Fluoride in Drinking Water
吃瓜不打烊 and California Healthline staff made the rounds on national and local media over the past two weeks to discuss recent stories. Here鈥檚 a collection of their appearances.
-
Journalists Take Stock of Opioid Settlement Payouts and Concierge Care Trend
吃瓜不打烊 staff made the rounds on state and local media in recent weeks to discuss stories they and their colleagues reported. Here鈥檚 a collection of their appearances.
-
The Path to a Better Tuberculosis Vaccine Runs Through Montana
Researchers at the University of Montana have pitched in to develop a more effective vaccine in the fight against an ancient disease that still kills an estimated 1.6 million people a year worldwide.
By Jim Robbins -
To Stop Fentanyl Deaths in Philadelphia, Knocking on Doors and Handing Out Overdose Kits
Facing widening racial disparities in overdose deaths, Philadelphia officials are sending workers and volunteers to knock on doors across the city, aiming to equip households with naloxone and other drug overdose prevention supplies. City officials hope a proactive approach will normalize naloxone as an everyday item in people鈥檚 medicine cabinets and prevent overdoses, especially among Black residents.
-
Readers Speak Up About Women’s Health Issues, From Reproductive Care to Drinking
吃瓜不打烊 gives readers a chance to comment on a recent batch of stories.